Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
76.87
-0.60 (-0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,487,026
Open
77.19
Bid (Size)
76.70 (5)
Ask (Size)
77.33 (1)
Prev. Close
77.47
Today's Range
76.75 - 77.49
52wk Range
60.47 - 87.67
Shares Outstanding
N/A
Dividend Yield
1.21%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
Today 14:37 EDT
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
Today 12:00 EDT
Via
Benzinga
Exposures
Fossil Fuels
Performance
YTD
+12.38%
+12.38%
1 Month
-4.97%
-4.97%
3 Month
-0.34%
-0.34%
6 Month
+13.55%
+13.55%
1 Year
+14.66%
+14.66%
More News
Read More
US Stocks Open Lower; Dow Tumbles Over 150 Points
Today 9:47 EDT
Via
Benzinga
Topics
Stocks
Exposures
US Equities
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
Today 8:04 EDT
Via
Benzinga
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
Today 7:00 EDT
From
AstraZeneca
Via
Business Wire
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Via
Benzinga
Exposures
Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Via
Investor's Business Daily
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
October 03, 2024
Via
Benzinga
Exposures
Product Safety
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
October 03, 2024
From
AstraZeneca
Via
Business Wire
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
October 01, 2024
Via
News Direct
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
October 01, 2024
From
AstraZeneca
Via
Business Wire
Is Summit Therapeutics Stock a Buy?
September 30, 2024
Via
The Motley Fool
Week In Review: Zenas Raises $259 Million In IPO
September 28, 2024
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Top Stock Reports For Toyota, AstraZeneca & Chubb
September 26, 2024
Via
Talk Markets
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
September 26, 2024
Via
Benzinga
Exposures
Product Safety
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
September 26, 2024
From
AstraZeneca
Via
Business Wire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
September 26, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
September 23, 2024
Via
Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
September 23, 2024
Via
Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
Via
Benzinga
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 23, 2024
From
AstraZeneca
Via
Business Wire
FLUMIST approved for self-administration in the US
September 20, 2024
From
AstraZeneca
Via
Business Wire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
September 19, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.